Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 789 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SCD Clear all
Recruiting Phase 2 Interventional

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

NCT07369024
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Completed No phase listed Observational

Patient and Physician Survey Determinants of Appropriate ICD Utilization

NCT01514773
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Not listed
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions
Metformin, Questionnaires
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 2:32 PM EDT
Active, not recruiting No phase listed Observational

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

NCT05675436
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Active, not recruiting Phase 1 Interventional

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

NCT03664830
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Peer Mentoring [PM], Structured Education Based Transition Program STE
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Mobile, Alabama • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Not applicable Interventional

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

NCT04691323
View directory record Official record
Conditions
Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions
HU-Go app
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis

NCT01848691
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Measurement of carbon monoxide level in exhaled breath
Other
Lead sponsor
Ashutosh Lal
Other
Eligibility
5 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions
rivaroxaban, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of IMR-687 in Healthy Adult Volunteers

NCT02998450
View directory record Official record
Conditions
Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions
IMR-687, Placebo Oral Capsule
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)

NCT00745420
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 23, 2026, 2:32 PM EDT
Recruiting No phase listed Observational

Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease

NCT06477289
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 25 Years
Enrollment
65 participants
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Increasing Physical Activity Through Social Support and Stress Resilience

NCT06896825
View directory record Official record
Conditions
Healthy, Subjective Cognitive Decline (SCD), Sedentary Behavior, Social Isolation in Older Adults
Interventions
Self-monitoring
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Acupuncture for Pain in Sickle Cell Disease

NCT04122378
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
acupuncture
Other
Lead sponsor
Deepika Darbari
Other
Eligibility
8 Years to 22 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 23, 2026, 2:32 PM EDT
Completed No phase listed Observational

The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease

NCT01591187
View directory record Official record
Conditions
Cancer, Sickle Cell Disease
Interventions
Text messaging, Questionnaire, Interviews
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 23, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional

Predictors of Pain in Sickle Cell Disease

NCT06139510
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Quantitative sensory testing
Other
Lead sponsor
Duke University
Other
Eligibility
15 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

NCT07252050
View directory record Official record
Conditions
Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Interventions
Ruxolitinib
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

NCT00061568
View directory record Official record
Conditions
Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 23, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 23, 2026, 2:32 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

NCT02041299
View directory record Official record
Conditions
Iron Overload, Sickle Cell Disease, Other Anemias
Interventions
Deferiprone, Deferoxamine
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
2 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 23, 2026, 2:32 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease

NCT01300221
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Drexel University
Other
Eligibility
1 Hour to 19 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 2:32 PM EDT